secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001558370-22-017015
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics Q3 2022 net loss $19.8M; XTX202 reaches target dose; XTX301 IND cleared
--------------------------------------------------------------------------------

- Cash $139.1M as of Sep 30, 2022; runway into Q2 2024.
- Net loss $19.8M in Q3 2022 vs $16.3M in Q3 2021; R&D expense $13.0M.
- XTX202 (IL-2) dosed at target 1 mg/kg; no vascular leak syndrome; CD8+ T cell increases seen.
- FDA cleared IND for XTX301 (IL-12); Phase 1 start expected Q1 2023.
- Company will seek partner for XTX101 (anti-CTLA-4); will not initiate a Phase 2 alone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/0001558370-22-017015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/xlo-20221109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer